|Articles|June 8, 2022
Tissue IHC: Translating Technology into Patient Testing After Biomarker Target is ID
Author(s)Frontage Laboratories, Inc.
In the discovery and investigation of novel biomarkers, tissue immunohistochemistry (IHC) studies are critical, but how do you translate the technology into the clinical laboratory for patient testing once a biomarker target has been identified?
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
Applied Clinical Trials' 2025 State of the Industry Survey
2
Do Phase II Protocol Learnings Help Simplify Phase III Protocol Designs?
3
The Confidence Trap in Clinical Trials: When Knowing Just Enough Becomes Dangerous
4
ACT Brief Weekly Recap: Clinical Research Faces Funding Strain, Data Evolution, and a Shift in Outsourcing Models
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
